Efficient adsorption of tumor necrosis factor with an in vitro set-up of the microspheres-based detoxification system

Blood Purification

Volumn 25, Issue 2, 2007, Pages 169-174

  Weber, Viktoria ^a   Hartmann, Jens ^a   Linsberger, Ingrid ^a   Falkenhagen, Dieter ^a  

^a DANUBE UNIVERSITY KREMS   (Austria)

Author keywords

Adsorption; Blood Purification; Sepsis; Tumor necrosis factor

Indexed keywords

ADSORBENT; ALBUMIN; CELLULOSE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ADSORPTION KINETICS; ARTICLE; BLOOD FILTER; BLOOD PURIFICATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOLOGICAL PROCEDURES; HUMAN; IN VITRO STUDY; INSTRUMENTATION; MICROSPHERE DETOXIFICATION SYSTEM; PLASMA; PRIORITY JOURNAL; SEPSIS;

ADSORPTION; HEMOPERFUSION; HUMANS; MICROSPHERES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947434034     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098434     Document Type: Article

References (21)

1. Bosch T, Wendler T: State of the art of low-density lipoprotein apheresis in the year 2003. Ther Apher Dial 2004;8:76-79.
2. Furst D, Felson D, Thoren G, Gendreau RM: Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomized trial. Ther Apher 2000;4:363-373.
3. Ullrich H, Kleinjung T, Steffens T, Jacob P, Schmitz G, Strutz J: Improved treatment of sudden hearing loss by specific fibrinogen apheresis. J Clin Apher 2004;19:71-78.
4. Rifai K, Ernst T, Kretschmer U, Bahr MJ, Schneider A, Hafer C, Haller H, Manns MP, Fliser D: Prometheus: a new extracorporeal system for the treatment of liver failure. J Hepatol 2003;39:984-990.
5. Falkenhagen, D, Schima, H, Loth, F: Arrangement for removing substances from liquids, in particular blood. Patent WO9504559; Japanese Patent # 50 1083 (1997); United States Patent # 5,855,782 (1999).
6. Falkenhagen D, Weber C, Schima H, Loth F, Rajnoch C, Vogt G, Moser H, Mitzner S: Eine neue Technologie der simultanen Filtration/Adsorption auf der Basis einer 'High-Speed' - Rezirkulation von Nano- und Microspheres für die extrakorporale Blutreinigung. Biomed Tech 1994;34 (suppl):105-108.
7. Eigler A, Sinha B, Hartmann G, Endres S: Taming TNF: strategies to restrain this pro-inflammatory cytokine. Immunol Today 1997;18:487-492.
8. Hehlgans T, Pfeffer K: The intriguing biology of the tumor necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005;115:1-20.
9. Zgangiacz A, Santosuosso M, Wang J, Yang T, Chen L, Anzulovic M, Alexander S, Gicquel B, Wan Y, Bramson J, Inman M, Xing Z: TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J Clin Invest 2004;113:401-413.
10. Echtenacher B, Urbaschek R, Weigl K, Freudenberg MA, Männel DN: Treatment of experimental sepsis-induced immunoparalysis with TNF. Immunobiology 2003;208:381-389.
11. Vandenabeele P, Declercq W, Beyaert R, Fiers W: Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995;5:392-399.
12. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McConough M, Scallon B, Moore MA, Vilcek J, Daddona P, Ghrayeb J: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-1453.
13. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-426.
14. Weber V, Linsberger I, Ettenauer M, Loth F, Höyhtyä M, Falkenhagen D: Development of specific adsorbents for tumor necrosis factor: influence of antibody immobilization on performance and biocompatibility. Biomacromolecules 2005;6:1864-1870.
15. Pennica D, Kohr WJ, Fendly BM, Shire SJ, Raab HE, Borchart PE, Lewis M, Goeddel DV: Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor-alpha induced receptor aggregation. Biochemistry 1992;31:1134-1141.
16. Bellomo R, Honoré P, Matson J, Ronco C, Winchester J: Extracorporeal blood treatment (EBT) methods in SIRS/sepsis. Int J Artif Organs 2005;28:450-458.
17. Ronco C, Bonello M, Bordoni V, Ricci Z, D́Intini V, Bellomo R, Levin N: Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif 2004;22:164-174.
18. Schroder J, Stuber F, Gallati H, Schade FU, Kremer B: Pattern of soluble TNF receptors I and II in sepsis. Infection 1995;23:143-148.
19. Falkenhagen D, Strobl W, Vogt G, Schrefl A, Linsberger I, Gerner FJ, Schoenhofen M: Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs 1999;23:81-86.
20. Peters T: All about Albumin. Biochemistry, Genetics, and Medical Applications. New York, Academic Press, 1996.
21. Dri P, Gasparini C, Menegazzi R, Cramer R, Albéri L, Presani G, Garbisa S, Patriarca P: TNF-induced shedding of TNF receptors in human polymorphonuclear leukocytes: role of the 55-kDa TNF receptor and involvement of a membrane-bound and non-matrix metalloproteinase. J Immunol 2000;165:2165-2172.